University of Tennessee West Cancer Center | Strategic Alliance Partners

West Cancer Center & Research Institute is the leader in comprehensive adult cancer care led by providers to provide the most positive outcomes though research, novel therapies, advanced treatments, and cancer prevention to all patients, regardless of socioeconomic status. With over 40 years of oncology expertise, 100+ specialists, 8 locations and over 47,000 patients in 2021- West is positioned as the first choice for cancer care in the Mid-South and a national model for comprehensive care.

Connect with us:

Latest from University of Tennessee West Cancer Center

Dr. Vidal on the Role of Social Determinants of Health in Breast Cancer Care

March 02, 2023

Video

Gregory Vidal, MD, PhD, discusses racial disparities in the treatment of patients with breast cancer.

Dr. Vidal on the Lasting Impact of the KATHERINE Trial in HER2-Positive Breast Cancer

July 07, 2022

Video

Gregory Vidal, MD, PhD, discusses the impact of the phase 3 KATHERINE trial in HER2-positive breast cancer.

New Findings in Breast Cancer Trials Call for Restructuring of Disease Subtypes

July 06, 2022

Article

Gregory Vidal, MD, PhD, including the evolution of treatment options for HER2-low breast cancer, emerging antibody-drug conjugates in triple-negative disease, and the viability of HER3 as an emerging target in breast cancer

Enobosarm Generates Overdue Excitement in AR+/ER+ Metastatic Breast Cancer

December 22, 2021

Article

Lee S. Schwartzberg, MD, discusses the culmination of research with androgen-targeted agents in metastatic androgen receptor–positive, estrogen receptor–positive breast cancer and ongoing research that could lead to a paradigm shift in the second-line setting.

Schwartzberg on Bringing Seminal Observations on AR From Bench to Bedside in ER+ Breast Cancer

December 20, 2021

Podcast

Dr. Schwartzberg discusses the rationale to evaluate enobosarm in androgen receptor-positive, estrogen recepetor-positive advanced breast cancer, phase 2 data with the agent, and expectations for the ongoing phase 3 ARTEST trial in this population.

West Cancer Center, Memphis Breast Cancer Consortium And Rabble Health Announce Initial Results Of Care Pathway Initiative

June 29, 2021

Article

Results from a partnership to address disparities and enhance the quality of breast cancer care atMemphis-based West Cancer Center & Research Institute were announced today.

West Joins ‘Advancing Inclusive Research’ Site Alliance

June 23, 2021

Article

Genentech, a member of the Roche Group, today announced the creation of the Advancing Inclusive Research® Site Alliance.

Dr. Grothey on the Potential Role of ctDNA as a Marker for Rechallenging Treatment in CRC

May 14, 2021

Video

Axel Grothey, MD, discusses the potential utility of circulating tumor DNA as a marker for rechallenging patients with treatment in colorectal cancer.

Dr. Grothey on the Potential Role of ctDNA in Screening for CRC

May 05, 2021

Video

Axel Grothey, MD, discusses the potential role of circulating tumor DNA testing in screening patients for early-stage colorectal cancer.

ctDNA Scratches the Surface in Colorectal Cancer

April 05, 2021

Article

Axel Grothey, MD, discusses the potential applications for ctDNA in CRC and shed light on the updated analysis from the pivotal IMbrave150 trial in advanced hepatocellular carcinoma.

Dr. Porter on Potential Sequencing With ADCs and TKIs in HER2+ Lung Cancer

March 31, 2021

Video

Jason Porter, MD, discusses potential sequencing strategies with antibody-drug conjugates and TKIs in HER2-positive lung cancer.

Portnoy Previews Immunotherapy Breakthroughs Shaking Up Frontline SCLC Paradigm

March 24, 2021

Article

David C. Portnoy, MD, FACP, discusses ongoing studies examining immunotherapy and what is needed to move the needle forward in SCLC.

Dr. Grothey on the Potential Utility of TAS-102/Bevacizumab in Metastatic CRC

March 08, 2021

Video

Axel Grothey, MD, discusses the potential utility of trifluridine/tipiracil in combination with bevacizumab in metastatic colorectal cancer.

Dr. Grothey on Dosing Strategies With Regorafenib in CRC

March 03, 2021

Video

Axel Grothey, MD, discusses dosing strategies with regorafenib in colorectal cancer.

Grothey Spotlights the Growing HER2+ Paradigm in GI Cancers

February 25, 2021

Podcast

Axel Grothey, MD, discusses the excitement surrounding HER2-directed therapies in gastrointestinal malignancies, the approval of trastuzumab deruxtecan in HER2-positive metastatic gastric/gastroesophageal junction cancer, and the investigational agents patritumab deruxtecan and zanidatamab that are poised to further advance the paradigm.

Dr. Grothey on the Rationale to Evaluate Patritumab Deruxtecan in HER3+ CRC

February 16, 2021

Video

Axel Grothey, MD, discusses the rationale to evaluate patritumab deruxtecan in HER3-positive colorectal cancer.

Trastuzumab Deruxtecan Slated for Study in HER2+ Gastric/GEJ Cancer

February 15, 2021

Article

Fam-trastuzumab deruxtecan-nxki is under study alone and in combination for the treatment of patients with HER2-overexpressing locally advanced, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma in the ongoing phase 1b/2 DESTINY-Gastric03 trial.

Dr. Grothey on Potential Combinations With Trastuzumab Deruxtecan in GI Malignancies

February 11, 2021

Video

Axel Grothey, MD, discusses potential combination strategies with fam-trastuzumab deruxtecan-nxki in gastrointestinal malignancies.

Grothey Spotlights Personalized Approaches Shaking Up CRC Care Continuum

February 10, 2021

Article

Axel Grothey, MD, highlights recent advancements in CRC treatment, including innovative combinations and emerging agents that are generating excitement in the field.

Dr. Grothey on the Results of the ANCHOR-CRC Trial in BRAF V600E-Mutant mCRC

January 04, 2021

Video

Axel Grothey, MD, discusses the results of the phase 2 ANCHOR-CRC trial in patients with BRAF-mutant metastatic colorectal cancer.